MARKET

VTYX

VTYX

Ventyx Biosciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.47
-0.76
-6.18%
Opening 11:32 06/29 EDT
OPEN
12.08
PREV CLOSE
12.22
HIGH
12.08
LOW
11.07
VOLUME
25.68K
TURNOVER
154.65K
52 WEEK HIGH
26.00
52 WEEK LOW
9.50
MARKET CAP
583.00M
P/E (TTM)
-6.5766
1D
5D
1M
3M
1Y
5Y
Ventyx Biosciences Announces Topline Phase 1 Data For Peripheral NLRP3 Inhibitor VTX2735
Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2 trial planned in CAPS patients to efficiently establish
Benzinga · 3h ago
BRIEF-Ventyx Biosciences Announces Positive Topline Phase 1 Data For Its Peripheral NLRP3 Inhibitor VTX2735
BRIEF-Ventyx Biosciences Announces Positive Topline Phase 1 Data For Its Peripheral NLRP3 Inhibitor VTX2735
Reuters · 3h ago
Ventyx Biosciences Says Anti-Inflammatory Drug Showed 'Excellent' Safety Profile in Phase 1 Trial
MT Newswires · 5h ago
Ventyx Biosciences to Participate in the Jefferies Healthcare Conference
ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant un...
GlobeNewswire · 06/01 12:00
‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy
Watch for these 3 catalysts and consider these 6 stocks.
marketwatch.com · 05/20 14:34
Ventyx Biosciences GAAP EPS of -$0.45 beats by $0.07
Ventyx Biosciences press release (NASDAQ:VTYX): Q1 GAAP EPS of -$0.45 beats by $0.07. Cash and cash equivalents of $273.14M
Seekingalpha · 05/12 20:30
BRIEF-Ventyx Biosciences Reports Q1 2022 Results
reuters.com · 05/12 20:03
Ventyx Biosciences Reports Narrower Than Expected Q1 Loss
MT Newswires · 05/12 17:15
More
No Data
Learn about the latest financial forecast of VTYX. Analyze the recent business situations of Ventyx Biosciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
57.14%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VTYX stock price target is 39.71 with a high estimate of 53.00 and a low estimate of 30.00.
High53.00
Average39.71
Low30.00
Current 11.47
EPS
Actual
Estimate
-2.54-1.90-1.27-0.63
Q4 2020
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 54
Institutional Holdings: 33.23M
% Owned: 65.35%
Shares Outstanding: 50.85M
TypeInstitutionsShares
Increased
10
930.11K
New
13
1.28M
Decreased
17
518.33K
Sold Out
5
68.14K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.01%
Pharmaceuticals & Medical Research
+0.66%
Key Executives
President
William Sandborn
Chief Executive Officer/Founder/Director/Primary Contact
Raju Mohan
Chief Scientific Officer
John Nuss
Vice President - Operations
Kathy Ogilvie
Executive Officer
Christopher Krueger
No Data
No Data
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet medical need. Its pipeline includes VTX958, VTX002, VTX2735 and Preclinical NLRP3 Inhibitor Portfolio. The Company’s lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus. It is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). The Company is also developing a NOD-like receptor protein 3 (NLRP3) inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Its NLRP3 inhibitor and VTX2735 designed to treat systemic inflammatory diseases such as cardiovascular, hepatic, renal, and rheumatologic diseases.

Webull offers kinds of Ventyx Biosciences Inc stock information, including NASDAQ:VTYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTYX stock methods without spending real money on the virtual paper trading platform.